Therapeutic Asset Ratings

13,145 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Dulaglutide Beta-Thalassemia Major	Ain Shams University	P2	B (57)
Durvalumab Cancer	Inimmune Corporation	P2	B (57)
Durvalumab BRCA2-Related Cancer Predisposition	European Organisation for Research and Treatment of Cancer - EORTC	P2	B (57)
Durvalumab Estrogen-Receptor Positive Breast Cancer	National Taiwan University Hospital	P2	B (57)
Durvalumab Gastric Adenocarcinoma	University of California, Irvine	P2	B (57)
Duvelisib Peripheral T-Cell Lymphoma, Not Otherwise Specified	City of Hope Medical Center	P2	B (57)
(E)-3-(2-((5-(3-(Phenylsulfonamido)Phenyl)Pent-4-En-1-Yl)Oxy)Phenyl)Propanoic Acid Chemotherapy-Induced Neuropathy	Ono Pharmaceutical Co., Ltd.	P2	B (57)
Edotreotide Pancreatic Neuroendocrine Tumor	ITM Solucin GmbH	P2	B (57)
Edotreotide Neoplasm	MedSIR	P2	B (57)
Efinopegdutide Metabolic Dysfunction-Associated Steatotic Liver Disease	Merck Sharp & Dohme LLC	P2	B (57)
Elpipodect Schizophrenia	Merck Sharp & Dohme LLC	P2	B (57)
Emestedastat Major Depressive Disorder	Actinogen Medical	P2	B (57)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Urethra Transitional Cell Carcinoma	National Cancer Institute (NCI)	P2	B (57)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Urinary Bladder Cancer	Fred Hutchinson Cancer Center	P2	B (57)
Epcoritamab Primary Mediastinal Large B-Cell Lymphoma	City of Hope Medical Center	P2	B (57)
Epinephrine Post-Operative Pain, Non-Human Animal	IVO JURISIC	P2	B (57)
Eribulin/Farletuzumab Antibody Drug Conjugate Ovarian Neoplasm	Bristol-Myers Squibb	P2	B (57)
Etoposide Ovarian Carcinoma	Fudan University	P2	B (57)
Etrumadenant Lung Cancer	Gilead Sciences	P2	B (57)
Everolimus Pancreatic Neuroendocrine Tumor G1	AC Camargo Cancer Center	P2	B (57)
Exemestane HER2 Positive Breast Carcinoma	Fudan University	P2	B (57)
Exemestane Prostate Cancer	OHSU Knight Cancer Institute	P2	B (57)
Ezabenlimab Metastatic Malignant Neoplasm	Boehringer Ingelheim	P2	B (57)
Ezabenlimab Neoplasm	Boehringer Ingelheim	P2	B (57)
Famitinib Small Cell Lung Carcinoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	B (57)

Showing 2801 to 2825 of 13,145 assets

PreviousPage 113 of 526Next